PubMed Health⌕ Search

Biomedical subjects

S M Rowe

Publications and source records attributed to S M Rowe.

24 records · Page 2Linked to original sources
PubMed1991

Bent plate fixation in combined intertrochanteric and subtrochanteric fractures of the femur.

Twenty-five combined intertrochanteric and subtrochanteric fractures of the femur (Type IV of Kyle's or Type V of Seinsheimer's classification) were treated with a bent plate and followed up through union (average: 2 years). All of the patients received immediate supplementary bone grafting and additional external supports. All but one of the fractures united between 3 and 6 months. Complications were: delayed union (1 case), which was treated by bone graft, trochanteric bursitis (3), and mild coxa vara (2). Anatomical reduction of scattered fragments and its maintenance through bony union were achieved in all cases. The bent plate provided excellent fixation in combined intertrochanteric and subtrochanteric fracture of the femur, and could be a successful alternative for these combined fractures.

Adult↗
PubMed1989

The use of alpha-aminoboronic acid derivatives to stabilize peptide drugs during their intranasal absorption.

alpha-Aminoboronic acid derivatives, potent and reversible inhibitors of aminopeptidases, were tested nasally in situ in rats for stabilizing externally administered peptides. These inhibitors, at nanomolar concentrations, were found to inhibit greatly the degradation of the model peptide, leucine-enkephalin (Leu-enk) in the nasal perfusate. Enzyme inhibition was greater with boroleucine and borovaline than that observed with boroalanine. Boroleucine was more than 100 times more effective in enzyme inhibition than bestatin and more than 1000 times more effective than puromycin.

Administration, Intranasal↗
PubMed1989

Osteochondritis dissecans in Perthes' disease. Report of 7 cases.

We report 7 cases of osteochondritis dissecans following Perthes' disease in 363 hips, i.e., an incidence of 2 percent. Six of the 7 cases belonged to Salter group B (Catterall Groups III-IV), indicating a higher incidence in hips with a worse prognosis. Six cases were asymptomatic and did not require treatment; in 3 of these, there was spontaneous radiographic healing of the lesion.

Adolescent↗
PubMedDate not supplied

Inhibition of leucine enkephalin metabolism in rat blood, plasma and tissues in vitro by an aminoboronic acid derivative.

Boroleucine, an aminoboronic acid derivative, is a potent inhibitor of aminopeptidases. Its effects on leucine enkephalin metabolism in rat whole blood, plasma and skeletal muscle and brain homogenates were determined in vitro. In the absence of the inhibitor, leucine enkephalin disappeared very rapidly from each medium. The rank order of metabolism rates was brain greater than muscle greater than whole blood approximately plasma. Des-tyrosyl-leucine enkephalin rapidly appeared as a result of metabolism by aminopeptidases. In whole blood and in the muscle and brain homogenates the aminopeptidase metabolite could account for all of the lost leucine enkephalin. In plasma, however, it appeared that another metabolic route contributed. Boroleucine prolonged the leucine enkephalin degradation half-life 1.6-1.9-fold in each medium at 0.1 microM concentrations, 1/1000th the concentration of leucine enkephalin. At 1.0 microM boroleucine concentrations the half-lives were prolonged 4.0-6.4-fold. Boroleucine also inhibited the degradation of des-tyrosyl-leucine enkephalin added to whole blood, but did not inhibit its degradation in muscle or brain homogenates. Boroleucine and other aminoboronic acid derivatives may be useful tools for studying peptide metabolism, and as pharmaceutical adjuvants to inhibit the degradation of peptide drugs metabolized by aminopeptidases.

Animals↗